The Rights Issue in summary:

• Subscription period: January 13, 2025 - February 24, 2025.
• Trade in unit rights:  January 13, 2025 - February 19, 2025.
• Preferential rights: Each share held on the record date of January 9, 2025, entitled the holder to one (1) unit right. Fifty (50) unit rights entitle the holder to pay and subscribe for one (1) unit.
• Unit: One (1) unit contains fifty (50) newly issued shares.
• Subscription price: SEK 0.23 per unit, corresponding to SEK 0.0046 per share.
• Issue proceeds: If fully subscribed, the Rights Issue will generate net proceeds of approximately SEK 22.9 million before issue costs.
• Underwritten level: The Rights issue is underwritten to approximately 60.0 percent through subscription and underwriting commitments.
• Share capital, shares and dilution: Through the Rights Issue, the share capital may increase by a minimum of approximately SEK 15,908,716.59 and by a maximum of approximately SEK 26,492,793.80, from approximately SEK 40,315,121.68 to a minimum of approximately SEK 56,223,838.27 and to a maximum of approximately SEK 66,807,915.48. The number of shares may increase by a maximum of 5,759,303,000 from 5,759,303,014 shares to a maximum of 11,518,606,014 shares. A fully subscribed Rights Issue entails a dilution corresponding to approximately 50.0 percent for Shareholders in the Company who do not participate in the Rights Issue.

Advisers

Mangold Fondkommission AB is financial adviser and Eversheds Sutherland Advokatbyrå AB is legal adviser to Peptonic in connection with the Rights Issue.

For more information contact:

Anna Linton, CEO Peptonic Medical AB

Email: anna.linton@peptonicmedical.se

Phone:  +46 70-244 92 07

About Peptonic Medical AB                                                                                                 

PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The Company is headquartered in Stockholm, Sweden, and operates a subsidiary, Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Peptonic in any jurisdiction, neither from Peptonic nor anyone else.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, South Africa, the United States, Belarus, or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This press release contains certain forward-looking information that reflects the Company's present view of future events as well as financial and operational development. Words such as "intend", "assess", "expect", "may", "plan", "believe", "estimate" and other expressions entailing indications or predictions of future development or trends, not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information is not a guarantee of future results or development and actual outcomes may differ materially from the statements set forth in the forward-looking information.